Review



pe anti human cd11c  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Elabscience Biotechnology pe anti human cd11c
    a Schematic illustration of the induction of M2 TAMs, the 1-6/TAM spheroids formulation, the transwell co-incubation, and their respective treatments. b Western blot analysis of GPX4 and FSP1 expression in M2 TAMs after different treatments. The experiment was repeated three times independently with similar results. Uncropped blots in Source Data. c Quantification of grayscale intensity of GPX4 and FSP1 in ( b ) ( n = 3 independent experiments). Protein expression levels in PBS group were normalized to 1. d Live/dead staining of M2 TAMs after different treatments (Scale bar = 200 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). The experiment was repeated three times independently with similar results. e Quantification of the percentage of viable and dead M2 TAMs in ( d ) ( n = 3 independent experiments). f Flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained M2 TAMs (gated on F4/80 + CD206 + macrophages) after different treatments. g Quantification of the percentage of apoptotic cells in ( f ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. h The cell proliferation of M2 TAMs after different treatments measured by CCK8 ( n = 3 independent experiments). The concentrations of SF and vF contained in nanoparticles were both 3 μM. i Fluorescence images of C11 BODIPY 581/591 -stained M2 TAMs after different treatments (Scale bar = 100 μm). The experiment was repeated three times independently with similar results. j Fluorescence images of live/dead stained 1-6/TAM spheroids after different treatments (Scale bar = 500 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). Z-stack scanning of the spheroids was performed with slices distanced by 14.36 μm. The experiment was repeated three times independently with similar results. k Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after different treatments. l Quantification of the percentage of CRT positive cells in ( k ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. m The ATP assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). n The HMGB1 assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). o Flow cytometric analysis of anti-CD80/CD86-stained BMDCs (gated on <t>CD11c</t> + DCs) after different treatments. p Quantification of the percentage of mature DCs in ( o ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. q The assay of TNF, IL-6, and IL-12 in BMDCs after different treatments ( n = 3 independent experiments). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , g , h , l – n , p , q ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 5a were created by Adobe Illustrator.
    Pe Anti Human Cd11c, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti human cd11c/product/Elabscience Biotechnology
    Average 93 stars, based on 3 article reviews
    pe anti human cd11c - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma"

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    Journal: Nature Communications

    doi: 10.1038/s41467-025-65056-9

    a Schematic illustration of the induction of M2 TAMs, the 1-6/TAM spheroids formulation, the transwell co-incubation, and their respective treatments. b Western blot analysis of GPX4 and FSP1 expression in M2 TAMs after different treatments. The experiment was repeated three times independently with similar results. Uncropped blots in Source Data. c Quantification of grayscale intensity of GPX4 and FSP1 in ( b ) ( n = 3 independent experiments). Protein expression levels in PBS group were normalized to 1. d Live/dead staining of M2 TAMs after different treatments (Scale bar = 200 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). The experiment was repeated three times independently with similar results. e Quantification of the percentage of viable and dead M2 TAMs in ( d ) ( n = 3 independent experiments). f Flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained M2 TAMs (gated on F4/80 + CD206 + macrophages) after different treatments. g Quantification of the percentage of apoptotic cells in ( f ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. h The cell proliferation of M2 TAMs after different treatments measured by CCK8 ( n = 3 independent experiments). The concentrations of SF and vF contained in nanoparticles were both 3 μM. i Fluorescence images of C11 BODIPY 581/591 -stained M2 TAMs after different treatments (Scale bar = 100 μm). The experiment was repeated three times independently with similar results. j Fluorescence images of live/dead stained 1-6/TAM spheroids after different treatments (Scale bar = 500 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). Z-stack scanning of the spheroids was performed with slices distanced by 14.36 μm. The experiment was repeated three times independently with similar results. k Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after different treatments. l Quantification of the percentage of CRT positive cells in ( k ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. m The ATP assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). n The HMGB1 assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). o Flow cytometric analysis of anti-CD80/CD86-stained BMDCs (gated on CD11c + DCs) after different treatments. p Quantification of the percentage of mature DCs in ( o ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. q The assay of TNF, IL-6, and IL-12 in BMDCs after different treatments ( n = 3 independent experiments). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , g , h , l – n , p , q ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 5a were created by Adobe Illustrator.
    Figure Legend Snippet: a Schematic illustration of the induction of M2 TAMs, the 1-6/TAM spheroids formulation, the transwell co-incubation, and their respective treatments. b Western blot analysis of GPX4 and FSP1 expression in M2 TAMs after different treatments. The experiment was repeated three times independently with similar results. Uncropped blots in Source Data. c Quantification of grayscale intensity of GPX4 and FSP1 in ( b ) ( n = 3 independent experiments). Protein expression levels in PBS group were normalized to 1. d Live/dead staining of M2 TAMs after different treatments (Scale bar = 200 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). The experiment was repeated three times independently with similar results. e Quantification of the percentage of viable and dead M2 TAMs in ( d ) ( n = 3 independent experiments). f Flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained M2 TAMs (gated on F4/80 + CD206 + macrophages) after different treatments. g Quantification of the percentage of apoptotic cells in ( f ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. h The cell proliferation of M2 TAMs after different treatments measured by CCK8 ( n = 3 independent experiments). The concentrations of SF and vF contained in nanoparticles were both 3 μM. i Fluorescence images of C11 BODIPY 581/591 -stained M2 TAMs after different treatments (Scale bar = 100 μm). The experiment was repeated three times independently with similar results. j Fluorescence images of live/dead stained 1-6/TAM spheroids after different treatments (Scale bar = 500 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). Z-stack scanning of the spheroids was performed with slices distanced by 14.36 μm. The experiment was repeated three times independently with similar results. k Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after different treatments. l Quantification of the percentage of CRT positive cells in ( k ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. m The ATP assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). n The HMGB1 assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). o Flow cytometric analysis of anti-CD80/CD86-stained BMDCs (gated on CD11c + DCs) after different treatments. p Quantification of the percentage of mature DCs in ( o ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. q The assay of TNF, IL-6, and IL-12 in BMDCs after different treatments ( n = 3 independent experiments). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , g , h , l – n , p , q ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 5a were created by Adobe Illustrator.

    Techniques Used: Formulation, Incubation, Western Blot, Expressing, Staining, Fluorescence, ATP Assay

    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.
    Figure Legend Snippet: a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.

    Techniques Used: Injection, Concentration Assay, Fluorescence, Imaging, Labeling, Staining

    a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.
    Figure Legend Snippet: a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.

    Techniques Used: Fluorescence, Immunofluorescence, Staining

    a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.
    Figure Legend Snippet: a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.

    Techniques Used: Immunofluorescence, Staining, Fluorescence



    Similar Products

    95
    Miltenyi Biotec human anti mouse cd11c igg antibody
    Human Anti Mouse Cd11c Igg Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human anti mouse cd11c igg antibody/product/Miltenyi Biotec
    Average 95 stars, based on 1 article reviews
    human anti mouse cd11c igg antibody - by Bioz Stars, 2026-06
    95/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology pe anti human cd11c
    a Schematic illustration of the induction of M2 TAMs, the 1-6/TAM spheroids formulation, the transwell co-incubation, and their respective treatments. b Western blot analysis of GPX4 and FSP1 expression in M2 TAMs after different treatments. The experiment was repeated three times independently with similar results. Uncropped blots in Source Data. c Quantification of grayscale intensity of GPX4 and FSP1 in ( b ) ( n = 3 independent experiments). Protein expression levels in PBS group were normalized to 1. d Live/dead staining of M2 TAMs after different treatments (Scale bar = 200 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). The experiment was repeated three times independently with similar results. e Quantification of the percentage of viable and dead M2 TAMs in ( d ) ( n = 3 independent experiments). f Flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained M2 TAMs (gated on F4/80 + CD206 + macrophages) after different treatments. g Quantification of the percentage of apoptotic cells in ( f ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. h The cell proliferation of M2 TAMs after different treatments measured by CCK8 ( n = 3 independent experiments). The concentrations of SF and vF contained in nanoparticles were both 3 μM. i Fluorescence images of C11 BODIPY 581/591 -stained M2 TAMs after different treatments (Scale bar = 100 μm). The experiment was repeated three times independently with similar results. j Fluorescence images of live/dead stained 1-6/TAM spheroids after different treatments (Scale bar = 500 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). Z-stack scanning of the spheroids was performed with slices distanced by 14.36 μm. The experiment was repeated three times independently with similar results. k Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after different treatments. l Quantification of the percentage of CRT positive cells in ( k ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. m The ATP assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). n The HMGB1 assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). o Flow cytometric analysis of anti-CD80/CD86-stained BMDCs (gated on <t>CD11c</t> + DCs) after different treatments. p Quantification of the percentage of mature DCs in ( o ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. q The assay of TNF, IL-6, and IL-12 in BMDCs after different treatments ( n = 3 independent experiments). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , g , h , l – n , p , q ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 5a were created by Adobe Illustrator.
    Pe Anti Human Cd11c, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti human cd11c/product/Elabscience Biotechnology
    Average 93 stars, based on 1 article reviews
    pe anti human cd11c - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    Cytek Biosciences mouse cd11c pe cy7 tonbo n418 60 0114 u100
    a Schematic illustration of the induction of M2 TAMs, the 1-6/TAM spheroids formulation, the transwell co-incubation, and their respective treatments. b Western blot analysis of GPX4 and FSP1 expression in M2 TAMs after different treatments. The experiment was repeated three times independently with similar results. Uncropped blots in Source Data. c Quantification of grayscale intensity of GPX4 and FSP1 in ( b ) ( n = 3 independent experiments). Protein expression levels in PBS group were normalized to 1. d Live/dead staining of M2 TAMs after different treatments (Scale bar = 200 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). The experiment was repeated three times independently with similar results. e Quantification of the percentage of viable and dead M2 TAMs in ( d ) ( n = 3 independent experiments). f Flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained M2 TAMs (gated on F4/80 + CD206 + macrophages) after different treatments. g Quantification of the percentage of apoptotic cells in ( f ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. h The cell proliferation of M2 TAMs after different treatments measured by CCK8 ( n = 3 independent experiments). The concentrations of SF and vF contained in nanoparticles were both 3 μM. i Fluorescence images of C11 BODIPY 581/591 -stained M2 TAMs after different treatments (Scale bar = 100 μm). The experiment was repeated three times independently with similar results. j Fluorescence images of live/dead stained 1-6/TAM spheroids after different treatments (Scale bar = 500 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). Z-stack scanning of the spheroids was performed with slices distanced by 14.36 μm. The experiment was repeated three times independently with similar results. k Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after different treatments. l Quantification of the percentage of CRT positive cells in ( k ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. m The ATP assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). n The HMGB1 assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). o Flow cytometric analysis of anti-CD80/CD86-stained BMDCs (gated on <t>CD11c</t> + DCs) after different treatments. p Quantification of the percentage of mature DCs in ( o ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. q The assay of TNF, IL-6, and IL-12 in BMDCs after different treatments ( n = 3 independent experiments). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , g , h , l – n , p , q ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 5a were created by Adobe Illustrator.
    Mouse Cd11c Pe Cy7 Tonbo N418 60 0114 U100, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse cd11c pe cy7 tonbo n418 60 0114 u100/product/Cytek Biosciences
    Average 93 stars, based on 1 article reviews
    mouse cd11c pe cy7 tonbo n418 60 0114 u100 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    90
    Thermo Fisher mouse anti-human cd11c pe-cy7
    Antibodies used for flow cytometry.
    Mouse Anti Human Cd11c Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-human cd11c pe-cy7/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    mouse anti-human cd11c pe-cy7 - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    92
    Proteintech cd11c pe mab
    Antibodies used for flow cytometry.
    Cd11c Pe Mab, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd11c pe mab/product/Proteintech
    Average 92 stars, based on 1 article reviews
    cd11c pe mab - by Bioz Stars, 2026-06
    92/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-human cd11c pe-cy7
    Antibodies used for flow cytometry.
    Anti Human Cd11c Pe Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-human cd11c pe-cy7/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-human cd11c pe-cy7 - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd11c antibody
    Antibodies used for flow cytometry.
    Cd11c Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd11c antibody/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    cd11c antibody - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd11c pe vio770
    Antibodies used for flow cytometry.
    Cd11c Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd11c pe vio770/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    cd11c pe vio770 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    Image Search Results


    a Schematic illustration of the induction of M2 TAMs, the 1-6/TAM spheroids formulation, the transwell co-incubation, and their respective treatments. b Western blot analysis of GPX4 and FSP1 expression in M2 TAMs after different treatments. The experiment was repeated three times independently with similar results. Uncropped blots in Source Data. c Quantification of grayscale intensity of GPX4 and FSP1 in ( b ) ( n = 3 independent experiments). Protein expression levels in PBS group were normalized to 1. d Live/dead staining of M2 TAMs after different treatments (Scale bar = 200 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). The experiment was repeated three times independently with similar results. e Quantification of the percentage of viable and dead M2 TAMs in ( d ) ( n = 3 independent experiments). f Flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained M2 TAMs (gated on F4/80 + CD206 + macrophages) after different treatments. g Quantification of the percentage of apoptotic cells in ( f ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. h The cell proliferation of M2 TAMs after different treatments measured by CCK8 ( n = 3 independent experiments). The concentrations of SF and vF contained in nanoparticles were both 3 μM. i Fluorescence images of C11 BODIPY 581/591 -stained M2 TAMs after different treatments (Scale bar = 100 μm). The experiment was repeated three times independently with similar results. j Fluorescence images of live/dead stained 1-6/TAM spheroids after different treatments (Scale bar = 500 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). Z-stack scanning of the spheroids was performed with slices distanced by 14.36 μm. The experiment was repeated three times independently with similar results. k Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after different treatments. l Quantification of the percentage of CRT positive cells in ( k ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. m The ATP assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). n The HMGB1 assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). o Flow cytometric analysis of anti-CD80/CD86-stained BMDCs (gated on CD11c + DCs) after different treatments. p Quantification of the percentage of mature DCs in ( o ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. q The assay of TNF, IL-6, and IL-12 in BMDCs after different treatments ( n = 3 independent experiments). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , g , h , l – n , p , q ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 5a were created by Adobe Illustrator.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Schematic illustration of the induction of M2 TAMs, the 1-6/TAM spheroids formulation, the transwell co-incubation, and their respective treatments. b Western blot analysis of GPX4 and FSP1 expression in M2 TAMs after different treatments. The experiment was repeated three times independently with similar results. Uncropped blots in Source Data. c Quantification of grayscale intensity of GPX4 and FSP1 in ( b ) ( n = 3 independent experiments). Protein expression levels in PBS group were normalized to 1. d Live/dead staining of M2 TAMs after different treatments (Scale bar = 200 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). The experiment was repeated three times independently with similar results. e Quantification of the percentage of viable and dead M2 TAMs in ( d ) ( n = 3 independent experiments). f Flow cytometric analysis of Annexin V-FITC/propidium iodide (PI)-stained M2 TAMs (gated on F4/80 + CD206 + macrophages) after different treatments. g Quantification of the percentage of apoptotic cells in ( f ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. h The cell proliferation of M2 TAMs after different treatments measured by CCK8 ( n = 3 independent experiments). The concentrations of SF and vF contained in nanoparticles were both 3 μM. i Fluorescence images of C11 BODIPY 581/591 -stained M2 TAMs after different treatments (Scale bar = 100 μm). The experiment was repeated three times independently with similar results. j Fluorescence images of live/dead stained 1-6/TAM spheroids after different treatments (Scale bar = 500 μm). Viable cells were stained with calcein-AM (green), and dead cells were stained with PI (red). Z-stack scanning of the spheroids was performed with slices distanced by 14.36 μm. The experiment was repeated three times independently with similar results. k Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after different treatments. l Quantification of the percentage of CRT positive cells in ( k ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. m The ATP assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). n The HMGB1 assay of Hepa1-6 cells after different treatments ( n = 3 independent experiments). o Flow cytometric analysis of anti-CD80/CD86-stained BMDCs (gated on CD11c + DCs) after different treatments. p Quantification of the percentage of mature DCs in ( o ) ( n = 3 independent replicates). The experiment was repeated twice independently with similar results. q The assay of TNF, IL-6, and IL-12 in BMDCs after different treatments ( n = 3 independent experiments). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , g , h , l – n , p , q ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 5a were created by Adobe Illustrator.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Formulation, Incubation, Western Blot, Expressing, Staining, Fluorescence, ATP Assay

    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Injection, Concentration Assay, Fluorescence, Imaging, Labeling, Staining

    a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Fluorescence, Immunofluorescence, Staining

    a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Immunofluorescence, Staining, Fluorescence

    Antibodies used for flow cytometry.

    Journal: Frontiers in Immunology

    Article Title: AIP56, an AB toxin secreted by Photobacterium damselae subsp. piscicida , has tropism for myeloid cells

    doi: 10.3389/fimmu.2024.1527088

    Figure Lengend Snippet: Antibodies used for flow cytometry.

    Article Snippet: , Mouse anti-human CD11c , PE-Cy7 , 3.9 , eBiosciences/25-0116-42.

    Techniques: Cytometry